State Street
BLTE

State Street’s Belite Bio BLTE Stock Holding History

State Street’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.56M Buy
16,048
+308
+2% +$51.8K ﹤0.01% 3219
2025
Q4 		$2.52M Buy
15,740
+2,467
+19% +$292K ﹤0.01% 3262
2025
Q3 		$982K Sell
13,273
-6,930
-34% -$455K ﹤0.01% 3515
2025
Q2 		$1.17M Buy
20,203
+105
+0.5% +$6.41K ﹤0.01% 3458
2025
Q1 		$1.33M Buy
20,098
+81
+0.4% +$4.88K ﹤0.01% 3367
2024
Q4 		$1.26M Sell
20,017
-69
-0.3% -$4.55K ﹤0.01% 3436
2024
Q3 		$942K Buy
20,086
+4,415
+28% +$214K ﹤0.01% 3496
2024
Q2 		$716K Sell
15,671
-999
-6% -$43.2K ﹤0.01% 3522
2024
Q1 		$640K Sell
16,670
-887
-5% -$39.7K ﹤0.01% 3585
2023
Q4 		$803K Buy
17,557
+592
+3% +$22.8K ﹤0.01% 3523
2023
Q3 		$536K Buy
16,965
+3,580
+27% +$89.7K ﹤0.01% 3650
2023
Q2 		$189K Buy
13,385
+921
+7% +$20.9K ﹤0.01% 4023
2023
Q1 		$362K Buy
12,464
+696
+6% +$21.2K ﹤0.01% 3857
2022
Q4 		$360K Buy
11,768
+1,160
+11% +$34.2K ﹤0.01% 3879
2022
Q3 		$359K Buy
+10,608
New +$367K ﹤0.01% 3900

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street's BLTE Position: Q1 2026 in Review

State Street increased its Belite Bio (BLTE) stake by 2% in Q1 2026, buying an estimated $51.8K and bringing the position to 16,048 shares worth $2.56M. The position accounts for ﹤0.01% of the portfolio, ranked #3219.

State Street first reported a position in BLTE in Q3 2022 and has held it in 15 quarters since. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • State Street held 16,048 shares of Belite Bio worth $2.56M as of Q1 2026.
  • State Street bought 308 Belite Bio shares in Q1 2026, an estimated $51.8K.
  • Belite Bio made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3219 holding.
  • State Street first reported a position in Belite Bio in Q3 2022 and has held it in 15 quarters since.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.